This article is more than 5 years old. Information may no longer be current.

EyeTechCare receives CE mark extension for focused ultrasound therapy for glaucoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeTechCare has received CE mark extension for new indications for a focused ultrasound treatment to reduce IOP in glaucoma patients, according to a press release.

The treatment will now have a broader application for all patients with uncontrolled glaucoma, regardless of previous treatment, the release said.

“From now on, the treatment can be offered to a far greater number of patients. We are convinced that this new therapeutic procedure will soon play a key role in the management of glaucoma patients who are often apprehensive about having surgery,” Dietrich Wolf, CEO of EyeTechCare, said in the release.

Clinical trials for the EyeOP1 started in 2010, with the pilot, EyeMUST 1 and EyeMUST 2 studies having positive tolerance and efficacy results. In EyeMUST 3, 30 patients with uncontrolled glaucoma under hypotensive medical treatment showed successful results after 12 months, the release said.